These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 37242655)
1. Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. Ferro Desideri L; Traverso CE; Nicolò M; Munk MR Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242655 [TBL] [Abstract][Full Text] [Related]
2. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Agostini H; Abreu F; Baumal CR; Chang DS; G Csaky K; Demetriades AM; Kodjikian L; Lim JI; Margaron P; Monés JM; Peto T; Ricci F; Rüth M; Singh RP; Stoilov I; Swaminathan B; Willis JR; Westenskow PD Graefes Arch Clin Exp Ophthalmol; 2024 Jun; ():. PubMed ID: 38847896 [TBL] [Abstract][Full Text] [Related]
3. Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Nicolò M; Ferro Desideri L; Vagge A; Traverso CE Expert Opin Investig Drugs; 2021 Mar; 30(3):193-200. PubMed ID: 33471572 [TBL] [Abstract][Full Text] [Related]
4. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Penha FM; Masud M; Khanani ZA; Thomas M; Fong RD; Smith K; Chand A; Khan M; Gahn G; Melo GB; Khanani AM Int J Retina Vitreous; 2024 Jan; 10(1):5. PubMed ID: 38233896 [TBL] [Abstract][Full Text] [Related]
5. YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale. Eter N; Singh RP; Abreu F; Asik K; Basu K; Baumal C; Chang A; Csaky KG; Haskova Z; Lin H; Ruiz CQ; Ruamviboonsuk P; Silverman D; Wykoff CC; Willis JR Ophthalmol Sci; 2022 Mar; 2(1):100111. PubMed ID: 36246184 [TBL] [Abstract][Full Text] [Related]
6. The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases. Ferro Desideri L; Traverso CE; Nicolò M Expert Opin Ther Targets; 2022 Feb; 26(2):145-154. PubMed ID: 35098845 [TBL] [Abstract][Full Text] [Related]
7. Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review. Liberski S; Wichrowska M; Kocięcki J Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012690 [TBL] [Abstract][Full Text] [Related]
9. Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab. Khan M; Aziz AA; Shafi NA; Abbas T; Khanani AM Cells; 2020 Aug; 9(8):. PubMed ID: 32785136 [TBL] [Abstract][Full Text] [Related]
10. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Wykoff CC; Abreu F; Adamis AP; Basu K; Eichenbaum DA; Haskova Z; Lin H; Loewenstein A; Mohan S; Pearce IA; Sakamoto T; Schlottmann PG; Silverman D; Sun JK; Wells JA; Willis JR; Tadayoni R; Lancet; 2022 Feb; 399(10326):741-755. PubMed ID: 35085503 [TBL] [Abstract][Full Text] [Related]
11. Angiopoietins as Potential Targets in Management of Retinal Disease. Khanani AM; Russell MW; Aziz AA; Danzig CJ; Weng CY; Eichenbaum DA; Singh RP Clin Ophthalmol; 2021; 15():3747-3755. PubMed ID: 34511878 [TBL] [Abstract][Full Text] [Related]
12. TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. Khanani AM; Guymer RH; Basu K; Boston H; Heier JS; Korobelnik JF; Kotecha A; Lin H; Silverman D; Swaminathan B; Willis JR; Yoon YH; Quezada-Ruiz C Ophthalmol Sci; 2021 Dec; 1(4):100076. PubMed ID: 36246941 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial. Mori R; Honda S; Gomi F; Tsujikawa A; Koizumi H; Ochi H; Ohsawa S; Okada AA; Jpn J Ophthalmol; 2023 May; 67(3):301-310. PubMed ID: 37039948 [TBL] [Abstract][Full Text] [Related]
14. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Hussain RM; Neiweem AE; Kansara V; Harris A; Ciulla TA Expert Opin Investig Drugs; 2019 Oct; 28(10):861-869. PubMed ID: 31513439 [No Abstract] [Full Text] [Related]
15. [Faricimab: from research to clinical practice]. Yusef YN; Budzinskaya MV; Plyukhova AA Vestn Oftalmol; 2023; 139(4):115-120. PubMed ID: 37638581 [TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes of a Loading Phase with Intravitreal Faricimab in Neovascular Age-Related Macular Degeneration (n-AMD) and Diabetic Macular Edema (DME). Giancipoli E; Guglielmi A; Bux AV; Clima GME; Pignatelli F; Boscia F; Viggiano P; Boscia G; Fortunato F; Besozzi G; Niro A; Dore S; Iaculli C Ophthalmol Ther; 2024 Aug; 13(8):2163-2184. PubMed ID: 38831127 [TBL] [Abstract][Full Text] [Related]
17. Faricimab: First Approval. Shirley M Drugs; 2022 May; 82(7):825-830. PubMed ID: 35474059 [TBL] [Abstract][Full Text] [Related]
18. Faricimab: Transforming the Future of Macular Diseases Treatment - A Comprehensive Review of Clinical Studies. Panos GD; Lakshmanan A; Dadoukis P; Ripa M; Motta L; Amoaku WM Drug Des Devel Ther; 2023; 17():2861-2873. PubMed ID: 37746113 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis. Yen WT; Wu CS; Yang CH; Chen YH; Lee CH; Hsu CR Sci Rep; 2024 Jan; 14(1):2485. PubMed ID: 38291069 [TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: A systematic review and meta-analysis of randomized clinical trials. Li G; Zhu N; Ji A Medicine (Baltimore); 2023 Dec; 102(50):e36370. PubMed ID: 38115358 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]